Document is current

Article History

Received: 19 April 2020

Accepted: 23 September 2020

First Online: 2 October 2020

Ethics approval and consent to participate

: The Gene-PARE was approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai and Florida Radiation Oncology Group. All patients provided informed consent under the parent study – Gene-PARE, at Icahn School of Medicine, Mount Sinai and Florida Radiation Oncology Group (see methods for references). We obtained access to anonymized individual level genotype data from Genetic Predictors of Adverse Radiotherapy Effects (Gene-PARE) (phs000772.v1.p1) via dbGaP’s authorized application, under the approval of North Texas Regional IRB protocol 2016–090. The study described here was performed under the North Texas Regional IRB (formerly the University of North Texas Health Science Center IRB), and was given “EXEMPT” status based on the criteria that our study involved data available from public repository, i.e. dbGaP and does not require approval of receiving informed consent from our institute. (dbGaP - ExternalRef removed).

: All authors on the manuscript have provided consent for publication. No individual data was used/discussed in the current manuscript.

: The authors have no competing interests to declare.